Yesterday, Archie Goodburn appeared on BBC Breakfast calling for a national brain cancer lead and better access to international clinical trials for UK patients. His message was clear, and the data backs it up.
Brain cancer is the biggest cancer killer of under-40s in the UK. Five-year survival sits at just 12.9%, compared to 56% across all cancers. Since 2002, brain cancer has received just 1% of national cancer research spend.
For glioblastoma specifically, the picture is even starker. Median survival for UK patients hasn't meaningfully improved in over 20 years. Clinical trials are running globally, but UK patients continue to face systemic barriers to access.
The Rare Cancers Act is a welcome step forward, but meaningful progress for brain cancer patients requires a dedicated approach: the right infrastructure, coordinated trial networks, and investment that matches the severity of the disease.
At QV Bioelectronics, we are developing the world's first fully implantable Tumour Treating Fields device for glioblastoma, with a long-term vision to treat a range of brain cancers. A stronger national framework and support for R&D isn't just a patient issue. It's what makes the UK a viable place to develop and deliver new therapies. Without it, innovation will move elsewhere.